Clinical trials: Survival , Tumor
Ovarian Neoplasm
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.
Ovarian cancer is a relatively uncommon but serious disease. It ranks 10th for female cancers, 5th for mortality, and its origin is still imperfectly known.
- Trial name
- BREIZH-PARPi (NCT04573933)
- Where
- 4 sites in France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Brest
Prostate Cancer, Prostate Cancer Recurrent
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed…
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- SPARKLE (NCT05352178)
- Testing
- Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy
- Where
- Belgium
- Volunteers
- 873 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04630015
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of California, San Francisco
Glioblastoma
Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients
This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in observation with brain MRI every 3 months and…
- Trial name
- PATSGO (NCT00643825)
- Testing
- Temozolomide
- Where
- Belgium
- Volunteers
- 64 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Glioblastoma Multiforme
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
The current study will investigate whether the addition of Neuradiab to surgery, radiation and adjuvant chemotherapy (temozolomide) will improve the survival of patients with glioblastoma and whether the drug regimen is safe.
- Trial name
- Glass-Art (NCT00615186)
- Testing
- Neuradiab + Radiotherapy + Temozolomide, Radiation Therapy + Temozolomide
- Volunteers
- 9 people
- Sponsor
- Bradmer Pharmaceuticals Inc.
Cancer
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
This phase III clinical trial will evaluate the impact on survival of adding chaplain-provided spiritual care or psychotherapy/meditation to standard-of-care (SOC) and palliative measures, plus chemotherapy if recommended, and…
- Trial name
- SPC (NCT07290491)
- Testing
- Chaplain-Provided Spiritual Care, Psychotherapy and Meditation Intervention
- Where
- United States
- Volunteers
- 854 people
- Sponsor
- The Methodist Hospital Research Institute
Esophageal Squamous Cell Carcinoma
Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
The goal of this multicenter retrospective cohort study is to evaluate the impact of different pathological regression types on survival and recurrence patterns, with a particular focus on ypT0N+ patients in patients with…
- Trial name
- NCT06241079
- Testing
- non-intervention
- Volunteers
- 582 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Retroperitoneal Sarcoma, Body Composition
Influence of Nutritional Status on Oncologic and Operative Outcome in Patients Operated for Retroperitoneal Sarcoma
This is a retrospective, observational study in consecutive patients operated on for primary RPS in the Institute of Oncology Ljubljana (Slovenia) between September 1999 and June 2020.
- Conditions
- Retroperitoneal Sarcoma, Body Composition, Malnutrition, Sarcopenia
- Trial name
- NCT05631379
- Testing
- Measurement of body composition with computed tomography (CT), GLIM malnutrition criteria, EWGSOP2 sarcopenia criteria
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- Institute of Oncology Ljubljana
Aging, Breast Cancer
The Value of Geriatric Assessments in Older Patients With Breast Cancer
Elderly cancer patients are a special group, often complicated by a variety of chronic diseases, which bring serious obstacles to surgery and adjuvant treatment.
- Conditions
- Aging, Breast Cancer, Chemotherapeutic Toxicity, Survival
- Trial name
- NCT03640117
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Weight Loss
Lifestyle, Exercise and Nutrition Study 1
The specific aims of this study are to determine the efficacy and cost-effectiveness of a weight loss program compared with usual care (control) treatment on 6-month changes in body weight, body fat, and serum hormones in breast…
- Trial name
- LEAN (NCT02109068)
- Testing
- Weight Loss Counseling- Phone, Weight Loss Counseling- In-Person
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Yale University
Hepatocellular Carcinoma, Transarterial Chemoembolization
Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma
The aim of this study was to evaluate whether survival of patients who underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.
- Trial name
- NCT01677468
- Testing
- Intermediate embolization, Complete embolization
- Where
- 3 sites in South Korea
- Volunteers
- 250 people
- Sponsor
- Hallym University Medical Center
Lung Cancer
Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers
Immunotherapy effectiveness and optimal combination strategy in lung cancers with EGFR uncommon and 20ins mutations was unclear.
- Trial name
- NCT06164574
- Testing
- Survival analysis
- Where
- China
- Volunteers
- 627 people
- Sponsor
- Haiquan Chen
Colorectal Cancer, Early Onset Colorectal Cancer
Multi-Center Study Protocol: Impact of Sarcopenia in Early-Onset Colorectal Cancer.
Sarcopenia's role in early-onset colorectal cancer (EOCRC), a subtype increasingly diagnosed in individuals under 50 years, has not yet been investigated according to recent literature.
- Conditions
- Colorectal Cancer, Early Onset Colorectal Cancer, Sarcopenia, Prognostic Factors
- Trial name
- ISoPECC (NCT06868095)
- Testing
- Surgical resection
- Volunteers
- 1,000 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival
A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy
This study is a multicenter cross-sectional survey of esophageal cancer patients who underwent radical chemoradiotherapy/radiotherapy from July 2017 to July 2020 in various medical centers, and who survived without disease…
- Trial name
- NCT05828875
- Testing
- questionnaire investigation
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Invasive Breast Cancer
Evaluation of the RESTART Survival Programme
The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022.
- Trial name
- NCT06283511
- Testing
- educational workshops
- Volunteers
- 200 people
- Sponsor
- Jules Bordet Institute
GIST
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Background: -Some people with wild-type gastrointestinal stromal tumors (WT-GIST) have a deficiency in one of their proteins called succinate dehydrogenase (SDH).
- Trial name
- NCT02015065
- Testing
- Vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Hepatectomy, Hepatocellular Carcinoma
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy…
- Conditions
- Hepatectomy, Hepatocellular Carcinoma, Sorafenib
- Trial name
- 2011PTAHCC (NCT01409499)
- Testing
- hepatic resection, transcatheter hepatic arterial chemoembolization, sorafenib
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.